CEBPZ and neurodegenerative disease: Moreover, the slight though not significant reduction of AUCDyn detected in APP23 mice could be driven by a reduction of CBF in transgenic mice already described in APP23 mice in a late stage of the pathology15 indicating that this is not the best method to measure it within the context of the neurodegenerative diseases.